309 related articles for article (PubMed ID: 27601343)
1. Potential impact of dengue vaccination: Insights from two large-scale phase III trials with a tetravalent dengue vaccine.
Coudeville L; Baurin N; L'Azou M; Guy B
Vaccine; 2016 Dec; 34(50):6426-6435. PubMed ID: 27601343
[TBL] [Abstract][Full Text] [Related]
2. Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies.
Coudeville L; Baurin N; Vergu E
Vaccine; 2016 Dec; 34(50):6417-6425. PubMed ID: 26614588
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
4. [Dengue fever: from disease to vaccination].
Teyssou R
Med Trop (Mars); 2009 Aug; 69(4):333-4. PubMed ID: 19725380
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
L'Azou M; Moureau A; Sarti E; Nealon J; Zambrano B; Wartel TA; Villar L; Capeding MR; Ochiai RL; ;
N Engl J Med; 2016 Mar; 374(12):1155-66. PubMed ID: 27007959
[TBL] [Abstract][Full Text] [Related]
6. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
[TBL] [Abstract][Full Text] [Related]
7. Dengue vaccine supplies under endemic and epidemic conditions in three dengue-endemic countries: Colombia, Thailand, and Vietnam.
Lee JS; Lim JK; Dang DA; Nguyen THA; Farlow A
Vaccine; 2017 Dec; 35(50):6957-6966. PubMed ID: 29110932
[TBL] [Abstract][Full Text] [Related]
8. Controlling dengue with vaccines in Thailand.
Chao DL; Halstead SB; Halloran ME; Longini IM
PLoS Negl Trop Dis; 2012; 6(10):e1876. PubMed ID: 23145197
[TBL] [Abstract][Full Text] [Related]
9. Projected Impact of Dengue Vaccination in Yucatán, Mexico.
Hladish TJ; Pearson CA; Chao DL; Rojas DP; Recchia GL; Gómez-Dantés H; Halloran ME; Pulliam JR; Longini IM
PLoS Negl Trop Dis; 2016 May; 10(5):e0004661. PubMed ID: 27227883
[TBL] [Abstract][Full Text] [Related]
10. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
Gessner BD; Wilder-Smith A
Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
Shim E
Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
[TBL] [Abstract][Full Text] [Related]
12. Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
Olivera-Botello G; Coudeville L; Fanouillere K; Guy B; Chambonneau L; Noriega F; Jackson N;
J Infect Dis; 2016 Oct; 214(7):994-1000. PubMed ID: 27418050
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
Moodie Z; Juraska M; Huang Y; Zhuang Y; Fong Y; Carpp LN; Self SG; Chambonneau L; Small R; Jackson N; Noriega F; Gilbert PB
J Infect Dis; 2018 Feb; 217(5):742-753. PubMed ID: 29194547
[TBL] [Abstract][Full Text] [Related]
14. Current issues in the economics of vaccination against dengue.
Tozan Y
Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
[TBL] [Abstract][Full Text] [Related]
15. A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia.
Lee JS; Lourenço J; Gupta S; Farlow A
Vaccine; 2018 Apr; 36(17):2346-2355. PubMed ID: 29573874
[TBL] [Abstract][Full Text] [Related]
16. Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials.
Plennevaux E; Moureau A; Arredondo-García JL; Villar L; Pitisuttithum P; Tran NH; Bonaparte M; Chansinghakul D; Coronel DL; L'Azou M; Ochiai RL; Toh ML; Noriega F; Bouckenooghe A
Clin Infect Dis; 2018 Apr; 66(8):1164-1172. PubMed ID: 29300876
[TBL] [Abstract][Full Text] [Related]
17. A role for vector control in dengue vaccine programs.
Christofferson RC; Mores CN
Vaccine; 2015 Dec; 33(50):7069-74. PubMed ID: 26478199
[TBL] [Abstract][Full Text] [Related]
18. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
[TBL] [Abstract][Full Text] [Related]
19. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.
Douglas DL; DeRoeck DA; Mahoney RT; Wichmann O
PLoS Negl Trop Dis; 2013; 7(3):e2127. PubMed ID: 23516658
[TBL] [Abstract][Full Text] [Related]
20. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
